1Y Target$12.66Near-term target
5Y Target$18.87Compound horizon
10Y Target$49.09Long-dated conviction
FCF-$450mTTM · 03/26FFCF is negative (-$450m) — cash-burning phase; acceptable only for pre-profit spec names · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev-7.6%TTM YoYDRevenue -7.6% — meaningful contraction
D/E0.12totalA-D/E 0.12 — conservative leverage, strong balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/S21.7xDP/S 21.7x — extreme, prices in flawless execution
PEG—proxy—PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Biotechnology · market cap $1.4b. 20% off the 52-week high of $11.66. Revenue -8% — in contraction; any catalyst that reverses this triggers re-rating.
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$450m) — capital raises or debt issuance likely required; dilution / leverage risk. Revenue contracting -8% — the operational turn is not yet visible in the top line. Currently unprofitable (margin -638.9%) — path to GAAP profitability is the core thesis risk.
Horizon
1-3 yr $12.66 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $18.87 — requires the platform / technology to reach commercial scale. 10 yr $49.09 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.